Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Jan 13;74(1):75–85. doi: 10.1111/j.1365-2125.2012.04173.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012 Boehringer Ingelheim. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society

PMC Copyright notice

Arithmetic mean plasma concentration–time profiles of linagliptin 5 mg after single oral doses (A) and at steady-state (B), and of CD1790 after single oral doses of linagliptin (C) and at steady-state (D) in healthy subjects (normal hepatic function) and patients with mild, moderate or severe hepatic impairment. (A and C) Normal hepatic function (n = 8) (); Mild hepatic impairment (n = 8) (); Moderate hepatic impairment (n = 9) (); Severe hepatic impairment (n = 8) (); (B and D) Normal hepatic function (n = 8) (); Mild hepatic impairment (n = 8) (); Moderate hepatic impairment (n = 8*) (); Severe hepatic impairment (median prediction^†) (); Severe hepatic impairment (5th percentile prediction^†) (); Severe hepatic impairment (95th percentile prediction^†) (). *Eight patients only completed the multiple dosing period in the moderate impairment group. †Distribution of predicted arithmetic mean steady-state profiles for severe hepatic impairment group (1000 simulated studies with n = 8)

Inline graphic — Arithmetic mean plasma concentration–time profiles of linagliptin 5 mg after single oral doses (A) and at steady-state (B), and of CD1790 after single oral doses of linagliptin (C) and at steady-state (D) in healthy subjects (normal hepatic function) and patients with mild, moderate or severe hepatic impairment. (A and C) Normal hepatic function (n = 8) (); Mild hepatic impairment (n = 8) (); Moderate hepatic impairment (n = 9) (); Severe hepatic impairment (n = 8) (); (B and D) Normal hepatic function (n = 8) (); Mild hepatic impairment (n = 8) (); Moderate hepatic impairment (n = 8*) (); Severe hepatic impairment (median prediction^†) (); Severe hepatic impairment (5th percentile prediction^†) (); Severe hepatic impairment (95th percentile prediction^†) (). *Eight patients only completed the multiple dosing period in the moderate impairment group. †Distribution of predicted arithmetic mean steady-state profiles for severe hepatic impairment group (1000 simulated studies with n = 8)